Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy

被引：32

作者：

Bahrami, Afsane ^{[1
,2
]}

Amerizadeh, Forouzan ^{[1
,2
]}

Hassanian, Seyed Mahdi ^{[3
,4
]}

ShahidSales, Soodabeh ^{[5
]}

Khazaei, Majid ^{[6
]}

Maftouh, Mina ^{[3
]}

Ghayour-Mobarhan, Majid ^{[3
]}

Ferns, Gordon A. ^{[7
]}

Avan, Amir ^{[3
]}

机构：

[1] Mashhad Univ Med Sci, Fac Med, Dept Modern Sci & Technol, Mashhad, Iran

[2] Mashhad Univ Med Sci, Fac Med, Student Res Comm, Mashhad, Iran

[3] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran

[4] Mashhad Univ Med Sci, Dept Med Biochem, Fac Med, Mashhad, Iran

[5] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Iran

[6] Mashhad Univ Med Sci, Fac Med, Dept Physiol, Mashhad, Iran

[7] Brighton & Sussex Med Sch, Div Med Educ, Brighton, Sussex, England

来源：

JOURNAL OF CELLULAR PHYSIOLOGY | 2018年 / 233卷 / 03期

关键词：

colorectal cancer; oxaliplatin; predictive biomarkers; resistance; DNA-REPAIR GENES; GLUTATHIONE-S-TRANSFERASE; GROWTH-FACTOR-RECEPTOR; MICROSATELLITE INSTABILITY; ADJUVANT CHEMOTHERAPY; CHROMOSOMAL INSTABILITY; THERAPEUTIC PROGNOSIS; FOLFOX-4; CHEMOTHERAPY; CISPLATIN RESISTANCE; CHINESE POPULATION;

D O I：

10.1002/jcp.25966

中图分类号：

Q2 [细胞生物学];

学科分类号：

071013 [干细胞生物学];

摘要：

Chemotherapy regimen containing oxaliplatin is often the first-line treatment for patient with advanced colorectal cancer. Oxaliplatin binds to DNA, leading to the formation of crosslinks and bulky adducts. Approximately 50% of patients with CRC benefit from treatment with oxaliplatin. It is possible that genetic variants in biological pathways involved in drug transportation, drug metabolism, DNA damage repair, and cell cycle modulation might affect the activity, or efficacy of oxaliplatin. Because oxaliplatin resistance may be related to these genetic variants and may therefore be an important reason for treatment failure, we have summarized the genetic variations that have been reported to be predictive markers of the response to oxaliplatin based therapy in patients with advanced CRC.

引用

页码：2193 / 2201

页数：9

共 72 条

[1]

Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer [J].